Cannabis Law Report

APRIL 27, 2022

MDMA-assisted therapy has already shown incredible results in the stage three clinical trials for individuals suffering from severe PTSD,” Ginal told committee members. “I The bipartisan and bicameral legislation is being sponsored by Reps. Patrick Neville (R) and David Ortiz (D), along with Sens.

Clinical Trials 52

Clinical Trials Legalization Therapy Food 52

Cannabis Law Report

JUNE 14, 2022

Those values guide our joint efforts to change perceptions about psychedelic assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens. Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 24, 2022

And the fact that the legislation is originating from leadership who is intimately familiar with drug policy reform is a firm indicator that this is a serious endeavor. Full story at. New Jersey Senate President Files Psilocybin Legalization Bill That Includes Home Grow Option, Unlike Current Marijuana Law.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

JUNE 20, 2021

The CIC consists of 97 members dedicated to ensuring a greater understanding of the role of medicinal cannabis, nutraceutical CBD, and hemp across the community and the advancement of medicinal cannabis as an alternate line of therapy.

Supply Chain 105

Supply Chain Clinical Trials Research and Development Medicine 105

Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

JANUARY 12, 2022

Today, Maya (Maya PBC) and the National Psychedelics Association (NPA) announced their partnership in support of the implementation of Oregon’s Measure 109, the first state-approved policy to allow the regulated use of psilocybin products in a facilitated setting. ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

APRIL 21, 2022

MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

Cannabis Law Report

OCTOBER 10, 2021

We at Cantourage share the belief that cannabis is a valuable medicine which until now has not gained enough attention as a therapy option. Provide guidance on clinical trials and plays integral role in bringing new product innovations to different markets in Europe (and beyond). pharmacology, toxicology, chemistry).

Clinical Trials 52

Clinical Trials Therapy Medicine Policy 52

Cannabis Law Report

NOVEMBER 15, 2021

PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA (pDNA) in the manufacture of cell and gene therapies (CGTs) and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. News release. FDA website. January 15, 2019. 2021.08.006.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 11 × 11. In 2017, the FDA designated MDMA a breakthrough therapy for PTSD.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

NOVEMBER 23, 2021

In a draft paper, Patents on Psychedelics: The Next Legal Battlefront of Drug Development , Senior Fellow at Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics Mason Marks and Harvard Law School Professor I.

Law 52

Law Research and Development Therapy Clinical Trials 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

JANUARY 19, 2022

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JUNE 19, 2022

The new center is designed to formalize a network of experts across the university based in a range of academic departments as well as existing centers focused on drug policy and substance misuse prevention and recovery. Davis and Slot predicted that as things stand, these therapies could be federally approved in three to five years. “If

Education 52

Education Research and Development Therapy Clinical Trials 52

Cannabis Law Report

MARCH 29, 2022

We are thrilled to have Michael’s expertise guiding the development of MDMA-assisted therapy for PTSD! Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA.

Therapy 52

Therapy Pharmaceutical Clinical Trials Access 52

The Cannigma

AUGUST 31, 2021

A 2018 research paper in the International Journal of Drug Policy analyzed in-depth interviews carried out with 24 Israeli physicians working in pain medicine, oncology, and family medicine, and found that “physicians discussed contrasting narratives of cananbi, presenting it as both a medicine and non-medicine.”

Education 101

Education Clinical Trials Medicine Policy 101

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. Legislation is pending, House Bill 37, to permit physicians to recommend cannabis therapy to those struggling with opioid abuse or dependence. AK resident? HI resident? CO resident?

Legislation 164

Legislation Decriminalization Access Therapy 164

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

JULY 25, 2022

Conversation Tackles MAPS Research Methadology & Issues Of Abuse In Therapy. Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. Psychedelics Today Podcast Interviews Rick Doblin.

Medicine 52

Medicine Therapy Research and Development Business 52

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Instead, qualifying evidence may come from adequate and well-controlled clinical trials. Phase I trials should be sufficient, and many have been completed using psilocybin.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

CannaTech

SEPTEMBER 23, 2019

The pleas of parents fighting to treat their sick children are impossible to ignore, as evidenced by the impact of Billy Caldwell and Alfie Dingley’s parents in shifting the regulatory framework for UK cannabis policy. UK cannabis policy is not serving the interests of patients.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. At 36, MAPS is now older than I was when I started MAPS at age 32.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

AUGUST 25, 2022

The MAPS Policy and Advocacy team coordinated a bipartisan coalition that met with U.S. Policy and Advocacy Director, MAPS. Its main focuses include establishing sentencing policies, advising Congress and the executive branch in developing criminal justice policy, and analyzing and distributing information on federal sentencing issues.

Research and Development 52

Research and Development Advocacy Clinical Trials Policy 52

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Therapy 89

Therapy Legalization Chronic Pain DEA 89

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? Seventy-six mostly male veterans between the ages of 24 and 77 completed the Phase 1 trial. Co-author Dr Sue Sisley says that the results are promising.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Cannabis Law Report

JUNE 3, 2022

We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. Provide legal advice for a wide range of clinical, licensing and regulatory matters. Roles and responsibilities.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59

Cannabis Law Report

MARCH 1, 2022

We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. Provide legal advice for a wide range of clinical, licensing and regulatory matters. Roles and responsibilities.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

OCTOBER 2, 2021

We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. Provide legal advice for a wide range of clinical, licensing and regulatory matters. Roles and responsibilities.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. It is unclear whether doctors are feeling completely reassured by laboratory and clinical trial research into medicinal cannabis.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

AUGUST 7, 2022

In recent years, as more clinical trial results show that psychedelics can be used in conjunction with therapy to treat illnesses like depression and post-traumatic stress disorder, legislators pushed to make certain substances available in certain settings. Psychedelic Alpha Policy Map. Where Laws Are Changing.

Law 74

Law Research and Development Therapy Treatment 74

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Veriheal

JULY 18, 2023

This could foster a pool of experts well-versed in applying psychedelic-assisted therapy. Clinical Trials and Reporting The bill breaks new ground by allowing clinical trials to take place regardless of whether the tested substances fall under federal or military statutes.

Treatment 98

Treatment Clinical Trials Research and Development Legislation 98

Cannabis Law Report

DECEMBER 30, 2019

After this historically successful year, we expect to see public and political support continue to increase in 2020 as more and more states implement sensible cannabis regulatory policies. “Never before in American history has marijuana policy advanced in Congress as far or as fast in one year as 2019. Erik Altieri.

Legislation 59

Legislation Patients Access Banking 59